TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07636590: Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

Sponsor: Claris Biotherapeutics, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 500 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07636590 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07636590 Rescue Dossier →